KB Home
KBH
Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
SYRE Spyre Therapeutics
- 17.020
- -1.140-6.28%
Close Mar 26 16:00 ET
- 17.030
- +0.010+0.06%
Post 16:27 ET
1.03BMarket Cap-5.35P/E (TTM)
18.780High16.930Low784.59KVolume18.250Open18.160Pre Close13.63MTurnover1.68%Turnover RatioLossP/E (Static)60.28MShares40.83552wk High2.83P/B793.48MFloat Cap16.93052wk Low--Dividend TTM46.62MShs Float318.750Historical High--Div YieldTTM10.19%Amplitude2.650Historical Low17.377Avg Price1Lot Size
Spyre Therapeutics News
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $71
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Promising Expansion in Rheumatoid Arthritis Drives Buy Rating for Spyre Therapeutics
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Promising Potential of Spyre Therapeutics' SPY002 Drives Buy Rating Amid Robust Anti-TL1A Market
Spyre Therapeutics Analyst Ratings
JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.